iifl-logo

Ajanta Pharma Ltd Board Meeting

2,617.75
(0.01%)
Apr 2, 2025|12:00:00 AM

Ajanta Pharma CORPORATE ACTIONS

02/04/2024calendar-icon
02/04/2025calendar-icon
PurposeBoard Meetings DateAnnouncement Date
Board Meeting30 Jan 202517 Jan 2025
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/01/2025 ,inter alia, to consider and approve Unaudited consolidated & standalone financial results of the Company for the third quarter and nine months ended 31st December 2024 PFA Results of 31st Dec 2024. (As per BSE Announcement Dated on 30/01/2025)
Board Meeting28 Oct 202417 Oct 2024
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/10/2024 inter alia to consider and approve unaudited consolidated and standalone financial results of the Company for the second quarter and half year ended 30th September 2024. Pursuant to Regulation 29(1)(e) and 42 of the Listing Regulations we hereby inform you that at the Board Meeting scheduled to be held on 28th October 2024, the Board of Directors will also consider declaration of 1st interim dividend for FY 2025 and fixation of record date of 6th November 2024. (As Per BSE Announcement Dated on: 23/10/2024) We hereby inform that the Board at the Board meeting held on Monday, 28th October 2024, has inter-alia approved the Unaudited (Consolidated & Standalone) Financial Results of the Company for the quarter and half year ended 30.09.2024 and declared 1st interim dividend for FY 2025. PFA enclosed outcome of Board Meeting for more details. 1st interim dividend for the year FY 2025. Each share of Rs. 2 face value will receive a dividend of Rs. 28, amounting to Rs. 350 cr. (As Per BSE Announcement Dated on 28.10.2024)
Board Meeting30 Jul 202417 Jul 2024
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2024 inter alia to consider and approve unaudited consolidated and standalone financial results of the Company for the first quarter ended 30th June 2024. PFA outcome of Board Meeting (As Per BSE Announcement dated on 30.07.2024)
Board Meeting2 May 202422 Apr 2024
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 inter alia to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2024; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2024. AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/05/2024 ,inter alia, to consider and approve Pursuant to Regulation 29(1)(b) of the Listing Regulations and in continuation to our intimation dated April 22, 2024 about meeting of the Board of Directors of the Company scheduled to be held on Thursday, May 2, 2024, we hereby inform that at the said meeting, the Board will also consider a proposal for buy-back of Equity Shares of the Company and other matters incidental and necessary thereto, in accordance with the applicable provisions of the Companies Act, 2013 (including the rules and regulations framed thereunder), the Securities and Exchange Board of India (Buy-back of Securities) Regulations, 2018, as amended, and other applicable laws (As Per BSE Announcement Dated on 26-04-2024) We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Pursuant to Regulation 30 of SEBI (LODR), we hereby inform that at the Board Meeting held today, the Board approved appointment of following persons as Additional Non-Executive Independent Director subject to approval of members: 1. Mr. David Rasquinha 2. Mrs. Medha Joshi 3. Mr. Rajesh Dalal 4. Mrs. Simi Thapar Pls find enclosed details towards: 1. Appointment of Cost Auditors 2. Vacancy of Cost Auditors 3. Re-appointment of Secretarial Auditors 4. Re-appointment of Tax Auditors We hereby inform that at the Board meeting held on Thursday, 2nd May 2024, Board has inter-alia approved the following: 1. Audited (Consolidated & Standalone) Financial Results of the Company for the quarter and year ended 31st March 2024. 2. Proposal of Buy Back. PFA enclosed outcome of Board Meeting for more details. Outcome of Board Meeting (As Per BSE Announcement Dated on 02.05.2024) In our intimation dated 2nd May 2024, under Regulation 30 of SEBI (LODR) Regulations, 2015, we had inadvertently intimated about change of Cost Auditor. PFA correct intimation for change in cost auditors. (As Per BSE Announcement Dated on 03/05/2024) PFA Board Resolution for Buy Back (As Per BSE Announcement Dated on 06.05.2024)

Ajanta Pharma: Related News

No Record Found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2025, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

ISO certification icon
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.